

# NEWS RELEASE



February 7th, 2020

## **Nippon Shinyaku signs a new co-promotion agreement with Janssen Pharmaceutical K.K. for ZYTIGA® in Japan**

Nippon Shinyaku Co., LTD. (Nippon Shinyaku; Headquarters, Kyoto; President, Shigenobu Maekawa) announced that Janssen Pharmaceutical K.K. (Janssen; Headquarters, Tokyo; President, Chris Hourigan) and Nippon Shinyaku entered into a new co-promotion agreement about ZYTIGA® (abiraterone acetate) for prostate cancer treatment in Japan.

This new agreement strengthens an already strong collaboration that will drive broader access to ZYTIGA® in Japan and complements the existing co-promotion agreement for ERLEADA® (apalutamide) with Nippon Shinyaku, which has been in place since January 2019.

Nippon Shinyaku will contribute the treatment of prostate cancer through providing appropriate medical information to medical facilities and collection of the information on ZYTIGA® in addition to ERLEADA® in cooperation with Janssen.

Under the agreement, both companies will start co-promoting ZYTIGA® to healthcare professionals in Japan from March 2, 2020, with Janssen retaining marketing authorization for ZYTIGA®.

### **About ZYTIGA®**

ZYTIGA® is a CYP17 inhibitor that exhibits anti-tumor effects by selectively inhibiting the androgen synthetic enzyme CYP17. It was first approved by the Ministry of Health, Labor and Welfare (MHLW) for the treatment of castration-resistant prostate cancer (CRPC) in July 2014 and approved for the treatment of hormone-naïve prostate cancer (HNPC) with high-risk prognostic factors in February 2018. It has been approved in more than 105 countries and to date, has been prescribed to more than 290,000 men worldwide.

### **About ERLEADA®**

ERLEADA® is a selective next generation oral androgen receptor inhibitor that inhibits the action of testosterone in prostate cancer cells and works by preventing androgen from binding to the androgen receptor (AR). It selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. ERLEADA was approved for the treatment for adults with castration-resistant prostate cancer without distant metastases in Japan in March 2019.

### **About Nippon Shinyaku**

Our mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, we aim to be an organization trusted by the community. Urology is the most focusing therapeutic area in Nippon Shinyaku. Please visit our website (<http://www.nippon-shinyaku.co.jp>) for products in urology etc.

### **Media Contact**

Corporate Communications Dept., Nippon Shinyaku